Temafloxacin Production Cost Reports

The report provides a detailed analysis essential for establishing a Temafloxacin production plant. It encompasses all critical aspects necessary for Temafloxacin production, including the cost of Temafloxacin production, Temafloxacin plant cost, Temafloxacin production costs, and the overall Temafloxacin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Temafloxacin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Temafloxacin is a broad-spectrum fluoroquinolone antibiotic that prevents bacterial DNA gyrase and topoisomerase IV. It disrupts DNA replication and transcription, effectively targeting both gram-positive and gram-negative pathogens like Streptococcus pneumoniae, Staphylococcus aureus, and anaerobes like Bacteroides fragilis.

It is utilised for treating lower respiratory tract infections like community-acquired pneumonia and acute exacerbations of chronic bronchitis. It is also employed for genitourinary infections like prostatitis, gonococcal urethritis, and uncomplicated urinary tract infections, which require only short 3-day regimens with high efficacy. It shows strong performance against skin and soft tissue infections. Its common side effects include nausea, diarrhoea, abdominal pain, fever, chills, jaundice, etc.

The market for Temafloxacin is driven by its usage as a potent broad-spectrum fluoroquinolone antibiotic. The growing demand for effective treatments against respiratory tract infections, urinary tract infections, and skin infections contributes to its market growth. The rising bacterial resistance and expanding healthcare access in different region fuels its market.

The industrial Temafloxacin procurement is influenced by competitive pricing from generic suppliers and high efficacy in short-course therapies, reducing hospitalisation costs. The regulatory approvals that focus on its safety profile post-reformulations, bulk tender opportunities in government hospitals, and favourable reimbursement policies further impact its sourcing. Also, growing awareness of its activity against multidrug-resistant pathogens further accelerates its market growth.

Raw Material for Temafloxacin Production

According to the Temafloxacin production plant project report, the key raw materials used in the production of Temafloxacin include 6,7-difluoroquinolone-3-carboxylic acid ester core and (R)- or (S)-3-methylpiperazine.

Manufactring Process of Temafloxacin

The extensive Temafloxacin production cost report consists of the following major industrial production process:

1. By Nucleophilic Displacement: The production process of  Temafloxacin involves nucleophilic displacement. The synthesis starts with a 6,7-difluoroquinolone-3-carboxylic acid ester core, where the 7-fluoro substituent undergoes nucleophilic displacement with chiral (R)- or (S)-3-methylpiperazine. This introduces the piperazinyl side chain at C7, yielding the enantiopure intermediates. The ester group hydrolyses under basic conditions to the carboxylic acid, followed by acidification and salt formation with HCl to produce Temafloxacin hydrochloride as the final product.

Temafloxacin is a fluoroquinolone antibiotic that has the molecular formula of C21H18F3N3O3 and a molecular weight of around 417.4 g/mol. It appears as a solid powder in free base or hydrochloride salt form with a molecular formula of 453.9 g/mol. It is hygroscopic and thermally stable with decomposition above 300 degree Celsius. It has low water solubility, slight DMSO solubility and a relative density of 1.43 g/cm³. It needs to be stored refrigerated or frozen under inert conditions. It has a pKa value of around 5.4 for the carboxylic acid and a logP value in the range 1.0–1.2, making it moderately lipophilic.